Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: J Immunol. 2020 Oct 28;205(11):3205–3217. doi: 10.4049/jimmunol.2000711

FIGURE 5. SPM adjuvant-enhanced P6 vaccination efficacy reduces SHS-exacerbated pulmonary immune cell infiltration following acute infection.

FIGURE 5.

SHS-exposed mice, (A) untreated or (B) treated with AT-RvD1 for 8 wks before vaccination with P6 ± SPM adjuvant 17-HDHA or AT-RvD1, were given acute pulmonary NTHI challenge 8 wks after the start of vaccination. (C) Total pulmonary immune cell infiltration at 4 and 24 h following acute infection was quantified as described in methods. All treatment groups were assayed at the same time, and data represent results generated from a single experiment using a total of n=30 mice at each time point. Data from individual mice are shown and the results are depicted as geometric mean ± 95% C.I. Statistical significance was determined as described in the methods section (overall p<0.0001 comparing SHS, P6+vehicle group vs all treatment groups with Tukey’s posttest for multiple comparisons at 4 and 24 h).